Seroatlas · Human Serome Atlas

CBLN2

Cerebellin-2

Also known as: CBLN2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IUK8
Gene: CBLN2
Ensembl: ENSG00000141668
Chromosome: 18
Canonical length: 224 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Cytosol,Perinuclear theca,Calyx,Flagellar centriole,Mid piece,Principal piece
Secretome location: Secreted in brain
Quaternary structure: Homohexamer

OverviewNCBI Gene

Predicted to be involved in maintenance of synapse structure and spontaneous synaptic transmission. Predicted to act upstream of or within positive regulation of synapse assembly. Predicted to be located in synaptic cleft. Predicted to be part of trans-synaptic protein complex. Predicted to be active in glutamatergic synapse. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

224 residues, UniProt reviewed canonical sequence.

>Q8IUK8|CBLN2
     1  MQAPGRGPLG LRLMMPGRRG ALREPGGCGS CLGVALALLL LLLPACCPVR AQNDTEPIVL
    61  EGKCLVVCDS SPSADGAVTS SLGISVRSGS AKVAFSATRS TNHEPSEMSN RTMTIYFDQV
   121  LVNIGNHFDL ASSIFVAPRK GIYSFSFHVV KVYNRQTIQV SLMQNGYPVI SAFAGDQDVT
   181  REAASNGVLL LMEREDKVHL KLERGNLMGG WKYSTFSGFL VFPL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CBLN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 38 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 38 nTPM
hypothalamus: 8.4 nTPM
midbrain: 5.3 nTPM
amygdala: 5.2 nTPM
seminal vesicle: 4.8 nTPM
retina: 4.7 nTPM

Single-cell type

brain excitatory neurons: 121 nCPM
mesothelial cells: 35 nCPM
epicardial cells: 23 nCPM
retinal amacrine cells: 18 nCPM
neuroendocrine cells: 14 nCPM
somatotrophs: 9 nCPM

Immune cell

naive B-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

cerebral cortex: 108 nTPM
white matter: 64 nTPM
basal ganglia: 53 nTPM
pons: 53 nTPM
thalamus: 48 nTPM
midbrain: 38 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.17
gnomAD pLI: 0.12
gnomAD missense Z: 1.87
DepMap mean gene effect: -0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CBLN2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CBLN2 as an antibody target. Whether an autoantibody or antibody against CBLN2 could matter depends on whether native CBLN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CBLN2 is annotated as secreted, so native CBLN2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CBLN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...